Methods of treating or preventing automimmune diseases with 2,4-pyrimidinediamine compounds

Details for Australian Patent Application No. 2003265336 (hide)

International Classifications

Event Publications

18 December 2003 Complete Application Filed

Priority application(s): 60/452,339 06.03.03 US; 60/443,949 31.01.03 US; 10/631,029 29.07.03 US; 10/631,029 29.07.03 US; 60/399,673 29.07.02 US

8 April 2004 Application Open to Public Inspection

Published as AU-B-2003265336

19 June 2008 Application Accepted

Published as AU-B-2003265336

16 October 2008 Standard Patent Sealed

23 April 2009 Corrigenda

Applications Accepted - Name Index Under the name Rigel Pharmaceuticals, Inc.. Application No. 2003265336, under INID(54), correct the title to Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

17 May 2012 Licence Registered

Rigel Pharmaceuticals, Inc. ( AstraZeneca AB )

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.